These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7477802)

  • 1. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa.
    Brambilla F; Draisci A; Peirone A; Brunetta M
    Neuropsychobiology; 1995; 32(2):68-71. PubMed ID: 7477802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa--binge-eating/purging type.
    Brambilla F; Draisci A; Peirone A; Brunetta M
    Neuropsychobiology; 1995; 32(2):64-7. PubMed ID: 7477801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type.
    Brambilla F; Draisci A; Peirone A; Brunetta M
    Neuropsychobiology; 1995; 32(2):59-63. PubMed ID: 7477800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa.
    Fichter MM; Leibl C; Krüger R; Rief W
    Pharmacopsychiatry; 1997 May; 30(3):85-92. PubMed ID: 9211569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.
    Fichter MM; Krüger R; Rief W; Holland R; Döhne J
    J Clin Psychopharmacol; 1996 Feb; 16(1):9-18. PubMed ID: 8834413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ghrelin concentrations and cardiac vagal tone are decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa.
    Tanaka M; Nakahara T; Muranaga T; Kojima S; Yasuhara D; Ueno H; Nakazato M; Inui A
    Horm Behav; 2006 Aug; 50(2):261-5. PubMed ID: 16643914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication and psychotherapy in the treatment of bulimia nervosa.
    Walsh BT; Wilson GT; Loeb KL; Devlin MJ; Pike KM; Roose SP; Fleiss J; Waternaux C
    Am J Psychiatry; 1997 Apr; 154(4):523-31. PubMed ID: 9090340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study.
    Ricca V; Mannucci E; Mezzani B; Moretti S; Di Bernardo M; Bertelli M; Rotella CM; Faravelli C
    Psychother Psychosom; 2001; 70(6):298-306. PubMed ID: 11598429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing cognitive behavioural therapy for eating disorders integrated with behavioural weight loss therapy to cognitive behavioural therapy-enhanced alone in overweight or obese people with bulimia nervosa or binge eating disorder: study protocol for a randomised controlled trial.
    Palavras MA; Hay P; Touyz S; Sainsbury A; da Luz F; Swinbourne J; Estella NM; Claudino A
    Trials; 2015 Dec; 16():578. PubMed ID: 26683478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa.
    Brambilla F; Brunetta M; Draisci A; Peirone A; Perna G; Sacerdote P; Manfredi B; Panerai AE
    Psychiatry Res; 1995 Nov; 59(1-2):51-6. PubMed ID: 8771220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study.
    Calandra C; Gulino V; Inserra L; Giuffrida A
    Eat Weight Disord; 1999 Dec; 4(4):207-10. PubMed ID: 10728184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cognitive-behavioral and supportive-expressive therapy for bulimia nervosa.
    Garner DM; Rockert W; Davis R; Garner MV; Olmsted MP; Eagle M
    Am J Psychiatry; 1993 Jan; 150(1):37-46. PubMed ID: 8417578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open trial of fluoxetine for adolescents with bulimia nervosa.
    Kotler LA; Devlin MJ; Davies M; Walsh BT
    J Child Adolesc Psychopharmacol; 2003; 13(3):329-35. PubMed ID: 14642021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpharmacologic treatments of bulimia nervosa.
    Agras WS
    J Clin Psychiatry; 1991 Oct; 52 Suppl():29-33. PubMed ID: 1938986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open trial of fluvoxamine in the treatment of bulimia nervosa.
    Ayuso-Gutierrez JL; Palazón M; Ayuso-Mateos JL
    Int J Eat Disord; 1994 Apr; 15(3):245-9. PubMed ID: 8199604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulimia nervosa.
    Hay P; Bacaltchuk J
    Clin Evid; 2004 Dec; (12):1326-47. PubMed ID: 15865722
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa.
    Ikenouchi-Sugita A; Yoshimura R; Hori H; Ueda N; Nakamura J
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):452. PubMed ID: 17610677
    [No Abstract]   [Full Text] [Related]  

  • 18. The fluoxetine treatment of low-weight, chronic bulimia nervosa.
    Solyom L; Solyom C; Ledwidge B
    J Clin Psychopharmacol; 1990 Dec; 10(6):421-5. PubMed ID: 2286712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of bulimia nervosa and binge eating disorder.
    Walsh BT; Devlin MJ
    Addict Behav; 1995; 20(6):757-64. PubMed ID: 8820528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison.
    Agras WS; Rossiter EM; Arnow B; Schneider JA; Telch CF; Raeburn SD; Bruce B; Perl M; Koran LM
    Am J Psychiatry; 1992 Jan; 149(1):82-7. PubMed ID: 1728190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.